Cefuroxime
- CAS No.
- 55268-75-2
- Chemical Name:
- Cefuroxime
- Synonyms
- CEFUROXIME AXETIL;Cefuroxime acid;cefuroxim;Cephuroxime;Cefuroxime VETRANAL;Cefuroxime Axetil EP Impurity D;-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;CXM;Ketocef;-7-((Z)
- CBNumber:
- CB7707485
- Molecular Formula:
- C16H16N4O8S
- Molecular Weight:
- 424.39
- MDL Number:
- MFCD00864889
- MOL File:
- 55268-75-2.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Product description | Number | Pack Size | Price |
| Cefuroxime VETRANAL | 34218 | 100mg | $329 |
| Cefuroxime | 444162 | 100mg | $468 |
| Cefuroxime | 444162 | 250mg | $885 |
| (6R,7R)-3-[[(Aminocarbonyl)oxy]methyl]-7-[[(2Z)-2-(2-furanyl)-2-(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid Asreported | 259820 | 1g | $333 |
| (6R,7R)-3-[[(Aminocarbonyl)oxy]methyl]-7-[[(2Z)-2-(2-furanyl)-2-(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid Asreported | 259820 | 2g | $476 |
| More product size | |||
| Melting point | 171.5-173°C |
|---|---|
| alpha | D20 +63.7° (c = 1.0 in 0.2M pH 7 phosphate buffer) |
| Density | 1.76 |
| refractive index | 1.6000 (estimate) |
| storage temp. | 2-8°C |
| solubility | DMSO (Slightly), Methanol (Slightly) |
| pka | pKa 2.5(H2O) (Uncertain) |
| form | Solid |
| color | White to Off-White |
| Water Solubility | 145mg/L at 25℃ |
| BCS Class | 4 |
| Major Application | clinical testing |
| InChIKey | JFPVXVDWJQMJEE-IZRZKJBUSA-N |
| SMILES | N12[C@@]([H])([C@H](NC(/C(/C3=CC=CO3)=N\OC)=O)C1=O)SCC(COC(N)=O)=C2C(O)=O |
| CAS DataBase Reference | 55268-75-2(CAS DataBase Reference) |
| FDA UNII | O1R9FJ93ED |
| ATC code | J01DC02,S01AA27 |
| EPA Substance Registry System | 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[(aminocarbonyl)oxy]methyl]-7-[[(2Z)-2-(2-furanyl)-2-(methoxyimino)acetyl]amino]-8-oxo-, (6R,7R)- (55268-75-2) |
| UNSPSC Code | 41116107 |
| NACRES | NA.24 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS08 |
|---|---|
| Signal word | Danger |
| Hazard statements | H334-H317 |
| Precautionary statements | P261-P272-P280-P302+P352-P333+P313-P321-P363-P501-P261-P285-P304+P341-P342+P311-P501 |
| PPE | Eyeshields, Gloves, type N95 (US) |
| Hazard Codes | Xn |
| Risk Statements | 42/43 |
| Safety Statements | 22-24-37-45 |
| WGK Germany | 3 |
| RTECS | XI0329000 |
| Storage Class | 11 - Combustible Solids |
| REACH Registrations | Active |
Cefuroxime price More Price(42)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | 34218 | Cefuroxime VETRANAL | 55268-75-2 | 100mg | $329 | 2026-04-30 | Buy |
| Usbiological | 444162 | Cefuroxime | 55268-75-2 | 100mg | $468 | 2026-06-03 | Buy |
| Usbiological | 444162 | Cefuroxime | 55268-75-2 | 250mg | $885 | 2026-06-03 | Buy |
| Usbiological | 259820 | (6R,7R)-3-[[(Aminocarbonyl)oxy]methyl]-7-[[(2Z)-2-(2-furanyl)-2-(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid Asreported | 55268-75-2 | 1g | $333 | 2026-06-03 | Buy |
| Usbiological | 259820 | (6R,7R)-3-[[(Aminocarbonyl)oxy]methyl]-7-[[(2Z)-2-(2-furanyl)-2-(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid Asreported | 55268-75-2 | 2g | $476 | 2026-06-03 | Buy |
Cefuroxime Chemical Properties,Uses,Production
Description
Cefuroxime axetil is the acetoxyethyl ester and oral prodrug of cefuroxime, a second-generation cephalosporin. It has a broad spectrum of action and is resistant to most P-lactamases. Cefuroxime axed is indicated for serious bacterial infections, especially where no identification of organism(s) has been made.
Chemical Properties
white crystalline solid
Originator
Glaxo (United Kingdom)
Uses
Cefuroxime is a second-generation cephalosporin antibiotic.
Uses
Antibacterial.
Definition
ChEBI: A 3-(carbamoyloxymethyl)cephalosporin compound having a 7-(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido side chain.
Application
Cefuroxime was synthesized by Glaxo Laboratories in 1975 as the first cephem antibiotic with the methoxyimino group at the 7 position. It is highly resistant to hydrolysis by cephalosporinase and is active against a variety of gram-negative bacteria, including indolepositive Proteus, Enterobacter, and Citrobacter. Cefuroxime is considered to be one of the socalled second-generation cephalosporins.
Manufacturing Process
A stirred mixture of N,N-dimethylacetamide (75 ml), acetonitrile (75 ml),
triethylamine (42 ml, 0.3 mol) and (6R,7R)-7-amino-3-carbamoyloxy-methylceph-3-em-4-carboxylic acid was immersed in an ice-bath and water
(10 ml) was added. The mixture was stirred at 0°C to 2°C for 45 minutes, the
solid slowly dissolving to give a yellow solution.
Meanwhile a stirred suspension of phosphorus pentachloride (14.99 g, 0.072
mol) in dry dichloromethane (150 ml) was cooled to 0°C, and N,N-dimethylacetamide (27.5 ml) was added. The resulting solution was recooled
to -10°C and 2-(fur-2-yl)-2-methoxyiminoacetic acid (synisomer) (12.17 g,
0.072 mol) was added. The mixture was stirred at -10°C for 15 minutes and
crushed ice (35 g) was added. The mixture was stirred at 0°C for 10minutes,
where after the lower dichloromethane phase was added over 10 minutes to
the cephalosporin solution prepared above, cooled to -10°C so that the
reaction temperature rose steadily to 0°C. The mixture was stirred at 0°C to
2°C for 1 hour, where after the cooling bath was removed and the reaction
temperature allowed to rise to 20°C over 1 hour. The reaction mixture was
then added slowly to 2 N hydrochloric acid (100 ml) diluted with cold water
(1.15 l) at 5°C. The pH of the two phase mixture was adjusted to below 2
with 2 N hydrochloric acid (10 ml), and the mixture was stirred and recooled
to 5°C. The solid which precipitated was filtered, washed with
dichloromethane (100 ml) and water (250 ml), and dried in vacuo at 40°C
overnight to give the title compound (22.04 g, 86.6%).
brand name
Zinnat
Therapeutic Function
Antibiotic
Antimicrobial activity
The methoximino side chain provides stability to most Gram-negative β-lactamases and it is active against most enterobacteria, including many multiresistant strains. Acinetobacter spp., S. marcescens and Ps. aeruginosa are resistant, although some Burkholderia cepacia strains are susceptible. Some anaerobic Gram-negative rods are susceptible, but B. fragilis is resistant. The minimum immobilizing concentration for the Nichol’s strain of T. pallidum is 0.01 mg/L.
Pharmacokinetics
Oral absorption (axetil): 40–50%
Cmax 500 mg intramuscular: c. 18–25 mg/L after 0.5–1 h
0.75 g intravenous infusion: c. 50 mg/L end infusion
500 mg oral (axetil): 6–9 mg/L after 1.8–2.5 h
Plasma half-life: 1.1–1.4 h
Volume of distribution: 11–15 L
Plasma protein binding: 30%
Absorption
The acetoxyethyl ester (cefuroxime axetil) is rapidly hydrolyzed on passage through the intestinal mucosa and in the portal circulation to liberate cefuroxime, acetaldehyde and acetic acid. No unchanged ester is detectable in the systemic circulation. Absorption is independent of dose in the range 0.25–1 g, and there is no accumulation on repeated dosing. Bioavailability is improved after food to around 50%. In elderly subjects receiving doses of 500 mg every 8–12 h, peak plasma levels were 5.5 mg/L after 1.5–2 h in the fasting state, rising to 7.6 mg/L after 20 min when the dose was administered with food.
Distribution
In patients with severe meningeal inflammation, the mean CSF concentration after a 1.5 g intravenous dose was in the range 1.5–3.7 mg/L. In about one-third of patients with normal CSF, no drug could be detected and in the remainder concentrations were 0.2–1 mg/L. In children treated for meningitis with 50 or 75 mg/kg, the CSF:serum ratios were 0.07 and 0.10, respectively. Concentrations in pleural drain fluid after thoracic surgery approximated to serum levels at 2 h after doses of 1 or 1.5 g and exceeded serum levels at 4 h, when they were still around 10 mg/L. Levels in pericardial fluid were similar, with fluid:serum ratios of 0.44 between 0.5 and 2 h. In patients receiving 1.5 g by intravenous bolus preoperatively, concentrations around 22 mg/g were found in subcutaneous tissue at about 5 h with an elimination half-life of about 1.5 h.
Mean bone:serum ratios in the femoral head after 750 mg intramuscular and 1.5 g intravenous bolus injections were 0.14 and 0.23, respectively. In patients with chronic otitis media treated with 0.75 g every 8 h for 6–8 days, peak concentrations in the middle ear of 0.7–1.7 mg/L were reached about 2 h after the dose. In patients given 750 mg intramuscularly on five consecutive days the mean sputum concentration rose from 0.57 mg/L on the first day to 1.15 mg/L on the third.
Excretion
The drug is excreted unchanged in the urine mostly within 6 h of administration, producing concentrations exceeding 1 g/L. About 45–55% of the drug is excreted by tubular secretion, so that the administration of probenecid increases the serum peak and prolongs the plasma half-life. Renal clearance is slightly affected by the route of administration but lies between 95 and 180 L/min. The plasma half-life is prolonged in the elderly up to 2.4 h.
Pharmacology
Cefuroxime acts bactericidally. It has a narrow spectrum of antimicrobial action. It is resistant to beta-lactamase action. It is highly active with respect to Gram-negative microorganisms (intestinal and hemophilial bacilli, salmonella, shigella, enterobacteria, and gonococci).
It is also active with respect to Gram-positive microorganisms (staphylococci, streptococci).
It is inactive with respect to various types of Pseudomonas, most strains of enterococci, many
strains of Enterobacter cloacae, methylcillin-resistant staphylococci, and L. monocytogenes.
It is used for bacterial infections caused by microorganisms that are sensitive to the drug.
These may be abdominal and gynecological infections, sepsis, meningitis, endocarditis, infections of the urinary and respiratory tracts, bones, joints, skin, and soft tissues. It is widely used
for pneumonia as well as bacterial meningitis in children, and for post-operational infectious
complications. Synonyms of this drug are ceftin, zinacef, curoxim, kefox, and many others.
Clinical Use
Cefuroxime axetil (Ceftin) is the 1-acetyoxyethyl ester ofcefuroxime. During absorption, this acid-stable, lipophilic,oral prodrug derivative of cefuroxime is hydrolyzed to cefuroximeby intestinal and/or plasma enzymes. The axetilester provides an oral bioavailability of 35% to 50% of cefuroxime,depending on conditions. Oral absorption of theester is increased by food but decreased by antacids and histamineH2-antagonists. The latter effect may be because ofspontaneous hydrolysis of the ester in the intestine becauseof the higher pH created by these drugs. Axetil is used forthe oral treatment of non–life-threatening infections causedby bacteria that are susceptible to cefuroxime. The prodrugform permits twice-a-day dosing for such infections.
Clinical Use
It has been used successfully to treat urinary, soft-tissue and pulmonary infections, as well as septicemia, and as a single- dose treatment (with probenecid) of gonorrhea due to β-lactamase-producing strains. It has been widely used for surgical prophylaxis.
Side effects
It is well tolerated with little pain or phlebitis on injection.
Minor hypersensitivity reactions and biochemical changes
common to cephalosporins are described.
The axetil ester may cause diarrhea and, in some cases,
vomiting. Changes in the bowel flora, sometimes with the
appearance of C. difficile, have been reported in about 15% of
patients. Vaginitis is reported in about 2% of female patients.
Synthesis
Cefuroxime, (Z)-mono(O-methyloxim) (6R,7R)-7-[2-(2-furyl)glyoxylamido]- 3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-2-carboxylic acid carbamate (32.1.2.18), is synthesized from 2-acetylfuran. Oxidizing this compound with nitrous acid gives 2-furylglyoxalic acid (32.1.2.15), which is reacted with methoxylamine to give the corresponding oxime, syn-2-methoxyamino-2-(2-furyl)acetic acid (32.1.2.16), which is then transformed into a mixed anhydride when reacted with oxaloyl chloride in diemethylformamide, and then reacted with benzhydryl ester of 7-aminocephalosporanic acid. The resulting product (32.1.2.17) undergoes enzymatic hydrolysis in an alkaline medium, in which the benzhydryl protection is not affected, and only the acetoxy group of the molecule at position C3 of the aminocephalosporanic acid is hydrolyzed. The resulting product with a free hydroxymethyl group (32.1.2.18) is reacted with chlorosulfonyl isocyanate, with intermediate formation of the corresponding N-chlorosulfonyl urethane (32.1.2.19), which is hydrolyzed by water to the urethane (32.1.2.20). Finally, removal of the benzhydryl protection using trifluoroacetic acid gives the desired cefuroxime (32.1.2.21).
Another simpler way of the synthesis of cefuroxime is by direct acylation of 7-amino- 3-aminocarbonyloxymethyl-3-cefem-4-carboxylic acid (32.1.2.22), which is isolated from the cultural fluid of Streptomyces lactamdurans, using syn-2-methoxyamino-2- (2-furyl)acetic acid chloride, which is synthesized by reacting the corresponding acid with phosphorous pentachloride.
Veterinary Drugs and Treatments
Cefuroxime is a semi-synthetic 2nd generation cephalosporin with enhanced activity against some gram-negative pathogens when compared to the first generation agents. Cefuroxime is available in both oral and parenteral dosage forms. It potentially may be useful in small animals when a cephalosporin is desired to treat bacterial infections susceptible to cefuroxime, but resistant to first generation cephalosporins, when enhanced gram-negative coverage is desired for surgery prophylaxis, or when high CNS levels are necessary. Little information is available with regard to its clinical use in small animals, however.
Cefuroxime Preparation Products And Raw materials
Raw materials
1of4
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shaanxi TNJONE Pharmaceutical Co., Ltd | sarah@tnjone.com | China | 1139 | 58 | |
| Shaanxi Xianhe Biotech Co., Ltd | +86-17709210191; +86-17709210191 | Jerry@xhobio.com | China | 901 | 58 |
| Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 | info@tianfuchem.com | China | 21533 | 55 |
| career henan chemical co | +86-0371-86658258 | sales@coreychem.com | China | 29766 | 58 |
| CONIER CHEM AND PHARMA LIMITED | sales@conier.com | China | 49906 | 58 | |
| Hefei Hangang Pharmaceutical Technology Co., Ltd. | +8618062405514 | ada@ipurechemical.com | China | 10224 | 58 |
| Hefei TNJ Chemical Industry Co.,Ltd. | +86-0551-65418671 +86-189 4982 3763 | sales@tnjchem.com | China | 34526 | 58 |
| Shaanxi Dideu Medichem Co. Ltd | +86-29-81139210 +86-17392587031 | 1059@dideu.com | China | 9984 | 58 |
| RongNa Biotechnology Co.,Ltd | +86-86-13583358881 +8618560316533 | Brad@rongnabiotech.com | China | 3373 | 58 |
| AFINE CHEMICALS LIMITED | +86-571-85134551 +86-18958018566 | info@afinechem.com | China | 15047 | 58 |
Related articles
- Cefuroxime: Antimicrobial Activity, Susceptibility, Administration and Dosage, Clinical Uses etc.
- Cefuroxime is a second-generation cephalosporin antibiotic, developed by Glaxo in the 1970s. It has been used worldwide for mo....
- Mar 22,2022
View Lastest Price from Cefuroxime manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-08-31 | Cefuroxime
55268-75-2
|
0.99 | RongNa Biotechnology Co.,Ltd | ||||
 |
2026-08-31 | Cefuroxime
55268-75-2
|
1KG | 98%min | 500kg | WUHAN FORTUNA CHEMICAL CO., LTD | ||
 |
2026-08-25 | Cefuroxime Axetil
55268-75-2
|
1kg | 0.99 | 1000kg | Shaanxi Xianhe Biotech Co., Ltd |
-
- Cefuroxime
55268-75-2
- 0.99
- RongNa Biotechnology Co.,Ltd
-
- Cefuroxime
55268-75-2
- 98%min
- WUHAN FORTUNA CHEMICAL CO., LTD
-
- Cefuroxime Axetil
55268-75-2
- $0.00
- 0.99
- Shaanxi Xianhe Biotech Co., Ltd
55268-75-2(Cefuroxime)Related Search:
1of4
